Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)
A Randomized Clinical Trial to Assess the Effects of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is right-handed
- Subject is in good health
- Subject is a nonsmoker
Exclusion Criteria:
- Subject works a night shift
- Subject has a history of any illness that might make participation in the study unsafe or confound the study results
- Subject has a history of head injury
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 3
Placebo
|
Single dose of placebo only in one of five treatment periods.
|
|
Experimental: 1
MK2637 120 mg
|
Single dose of 120 mg MK2637 capsules in one of five treatment periods.
|
|
Experimental: 2
MK2637 50 mg
|
Single dose of 50 mg MK2637 capsules in one of five treatment periods.
|
|
Active Comparator: 4
Dextromethorphan 220 mg
|
Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
|
|
Active Comparator: 5
Dextromethorphan 110 mg
|
Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Increase in Motor Evoked Potential (MEP) after dosing with dextromethorphan compared to placebo
Time Frame: 5 Hours after initial dosing
|
5 Hours after initial dosing
|
|
Increase in amplitude in the gamma frequency band (24-60 Hz) of resting qEEG after dosing with dextromethorphan compared to placebo
Time Frame: 4 Hours after initial dosing
|
4 Hours after initial dosing
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Increase in amplitude in the theta frequency band (4-8 Hz) of resting qEEG after dosing with MK2637 compared to placebo
Time Frame: 6.5 hours after initial dosing
|
6.5 hours after initial dosing
|
|
Change in Motor Evoked Potential (MEP) after dosing with MK2637 as compared to placebo
Time Frame: 5 hours after initial dosing
|
5 hours after initial dosing
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Respiratory System Agents
- Antitussive Agents
- Dextromethorphan
Other Study ID Numbers
Other Study ID Numbers
- 2637-008
- MK2637-008
- 2009_608
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.